Keywords
How to Cite
Abstract
The aim of this study was to evaluate steroid receptors’ status of tumor tissue in different molecular biological types of endometrial cancer (EC), subdivided according to the current classification, and their colonization by lymphocytic and macrophage cells, taking into account body mass index of the patients. Materials and methods: Material from treatment-naive patients with EC (total n = 229) was included; the number of sick persons varied depending on the method used. The average age of patients was close to 60 years, and about 90% of them were postmenopausal. It was possible to divide the results of the work into two main subgroups: a) depending on the molecular biological type of the tumor (determined on the basis of genetic and immunohistochemical analysis), and b) depending on the value of the body mass index (BMI). The latter approach was used in patients with EC type demonstrating a defective mismatch repair of the incorrectly paired nucleotides (MMR-D) and with a type without characteristic molecular profile signs (WCMP), but was not applied (due to the smaller number of patients) in EC types with a POLE gene mutation or with expression of the oncoprotein p53. According to the data obtained, when comparing various types of EC, the lowest values of Allred ER and PR scores were revealed for POLE-mutant and p53 types, while the “triple-negative” variant of the tumor (ER-, PR-, HER2/neu-) was most common in POLE-mutant (45.5% of cases) and WCMP (19.4%) types of EC. The p53+ type of EC is characterized by inclination to the higher expression of the macrophage marker CD68 and lymphocytic Foxp3, as well as mRNA of PD-1 and SALL4. In addition to the said above, for WCMP type of EC is peculiar, on the contrary, a decrease in the expression of lymphocytic markers CD8 (protein) and PD-L1 (mRNA). When assessing the role of BMI, its value of >30.0 (characteristic for obesity) was combined with an inclination to the increase of HER-2/neu expression in the case of MMR-D EC type and to the decrease of HER-2 /neu, FOXp3 and ER expression in WCMP type. Conclusions: The accumulated information (mainly describing here hormonal sensitivity of the tumor tissue and its lymphocytic-macrophage infiltration) additionally confirms our earlier expressed opinion that the differences between women with EC are determined by both the affiliation of the neoplasm to one or another molecular biological type (subdivided according to the contemporary classification), as well as by body mass value and (very likely) the associated hormonal and metabolic attributes.
References
Talhouk A, McConechy MK, Leung S et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. cancer. 2017,Vol.123(5):P.802-813. DOI: 10.1002/cncr.30496
Берштейн Л.М., Порошина Т.Е., Васильев Д.А., Коваленко И.М.,Иванцов А.О., Иевлева А.Г., Берлев И.В. Сравнительные особенности состояния углеводного обмена и массы тела при различных молекулярнобиологических типах рака эндометрия. Вопр. онкол, 2018, т. 64 (3): С.394-398.
Берштейн Л.М., Иевлева А.Г., Иванцов А.О., Васильев Д.А., Клещев М.А., Порошина Т.Е., Коваленко И.М., Венина А.Р., Берлев И.В. Современные молекулярно-биологические типы рака эндометрия: сравнительная эндокринная и провоспалительно-прогенотоксическая характеристика. Вопр.онкол. 2019, т.65 (2): С.272-278.
Berstein LM, lyevleva AG, Ivantsov AO, Vasilyev DA, Poroshina TE, Berlev IV. Endocrinology of obese and nonobese endometrial cancer patients: is there role of tumor molecular-biological type? Future Oncol. 2019, Vol. 15(12): P. 1335-1346. DOI: 10.2217/fon-2018-0687
Dun EC, Hanley K, Wieser F, Bohman S, Yu J, Taylor RN. Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Int J Gynecol Pathol. 2013; Vol.32(6): P.576-584. DOI: 10.1097/PGP.0b013e318284e198
Machida H, De Zoysa MX Takiuchi T, Hom Ms, Tierney KE, Matsuo K. significance of Monocyte Counts at Recurrence on survival Outcome of Women with Endometrial Cancer. Int J Gynecol Cancer. 2017; Vol. 27(2): P.302-310. DOI: 10.1097/IGC.0000000000000865
Talhouk A, Derocher H, schmidt P, Leung s, Milne K, Gilks CB et al. Molecular subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clin Cancer Res. 2019; Vol.25(8):P2537-2548. DOI: 10.1158/1078-0432.CCR-18-3241
de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, Nijman HW. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009; Vol.114(1):P105-110. DOI: 10.1016/j.ygyno.2009.03.022
Леенман Е.Е., Мухина М.С. Клеточное микроокружение злокачественных опухолей и его значение в прогнозе // Вопр.онкол. 2013. Т.59(4). С.444-452.
Перельмутер В.М., Таширева Л.А., Манских В.Н., Денисов Е.В., Савельева О.Е., Кайгородова Е.В., Завьялова М.В. Иммуновоспалительные реакции в микроокружении гетерогенны, пластичны, определяют противоопухолевый эффект или агрессивное поведение опухоли.Журнал общей биологии2017, Т.78(5), С.15-36.
Иммунная система и эффективность противоопухолевого лечения /Ю. Г. Кжышковска, М. Н. Стахеева, Н. В. Литвяков, О. Е. Савельева, И. В. Митрофанова, И. В. Степанов, А. Н. Грачев, Т. С. Геращенко, М. В. Завьялова, Н. В. Чердынцева.; под ред. Ю. Г. Кжышковской, Н. В. Чердынцевой; Томский гос. ун-т, Томский НИИ онкологии. - Томск: Изд-во ТГУ, 2015. - 164 с. - IsBN - 978-5-7511-2391-8. DOI: 10.172239785-7511-2391-8
Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Bosse T. et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology. 2016; Vol.6(2):e1264565. DOI: 10.1080/2162402X.2016.1264565
Gadducci A, Guerrieri ME. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. Anticancer Res. 2017; Vol. 37(11): P5955-5965.
De Felice F, Marchetti C, Tombolini V, Panici PB. Immune check-point in endometrial cancer. Int J Clin Oncol. 2019; Vol. 24(8): P910-916. DOI: 10.1007/s10147-019-01437-7
Szylberg t, Karbownik D, Marszalek A. The Role of FOXP3 in Human Cancers. Anticancer Res. 2016; Vol. 36(8): P.3789-3794.
Keir ME, Butte MJ, Freeman GJ, sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; Vol.26: P677-704
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;Vol. 12: P.252-264
Gao C, Kong NR, Li A, Tatetu H, Ueno S, Yang Y. et al. sALL4 is a key transcription regulator in normal human hematopoiesis. Transfusion. 2013; Vol.53(5):P 1037-1049. DOI: 10.1111/j.1537-2995.2012.03888.x
Li A, Jiao Y, Yong KJ, Wang F, Gao C, Yan B et al. sALL4 is a new target in endometrial cancer. Oncogene. 2015; Vol.34(1):P63-72. DOI: 10.1038/onc.2013.529
Onstad MA, schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. J Clin Oncol. 2016;Vol.34(35):P4225-4230.
stelloo E, Jansen AML, Osse EM et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017, Vol.28(1): P 96-102.
Mitiushkina NV, Iyevleva AG, Poltoratskiy AN, Ivantsov AO, Togo AV, Polyakov Is et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol Vol.2013; P121:370-376.
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; Vol.17(5): P1474-1481.
Łapinska-szumczyk SM, Supernat AM, Majewska HI, Gulczynski J, Biernat W, Wydra D, Zaczek AJ. Immunohistochemical characterisation of molecular subtypes in endometrial cancer. Int J Clin Exp Med. 2015; Vol. 8(11):21981-21990.
Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015; 1(9):1319-1323.
Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L et al. Tumor genotype and immune microenvironment in POLE-ultramutated and MsI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? Cancer Treat Rev. 2016;48:61-68.
Asaka S, Yen TT, Wang TL, Shih IM, Gaillard S. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol. 2019; 32(4): 576-584.
Erber R, Stöhr R, Herlein S, Giedl C, Rieker RJ, Fuchs F et al. Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. Anticancer Res. 2017; 37(12):6771-6778.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020